SCHEMBL20147393

SCHEMBL20147393

CC(C)N1CCC(O)(Cc2cccnc2)CC1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
OPRM1 P35372 2/20 0.49
OPRD1 P41143 2/20 0.49
OPRK1 P41145 2/20 0.49
OPRL1 P41146 2/20 0.49
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
PKM P14618 1/20 0.42
RAB9A P51151 1/20 0.42
KMT2A Q03164 1/20 0.42
PKLR P30613 2/20 0.41
CHRNB2 P17787 1/20 0.41
CHRNA4 P43681 1/20 0.41
CYP46A1 Q9Y6A2 4/20 0.40
VNN1 O95497 1/20 0.40
CYP3A4 P08684 1/20 0.39
CYP2C8 P10632 1/20 0.39
CYP2C9 P11712 1/20 0.39
CYP2C19 P33261 1/20 0.39
CYP2D6 P10635 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20069624 0.88 OPRM1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL20147410 0.86 OPRM1 (0.43) OPRM1OPRD1OPRK1OPRL1CHRNB2
SCHEMBL21651922 0.84 ALDH1A1 (0.48) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL9963238 0.82 OPRL1 (0.69) OPRM1OPRD1OPRK1OPRL1MEN1
SCHEMBL25517289 0.82 CHRNB2 (0.48) OPRL1ALDH1A1CHRNB2CHRNA4CYP3A4
SCHEMBL20158572 0.82 ALDH1A1 (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL20206043 0.81 CHRNB2 (0.44) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL16051082 0.81 PKLR (0.46) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL22856988 0.78 PKLR (0.41) OPRM1OPRD1OPRK1OPRL1ALDH1A1
SCHEMBL20147392 0.77 OPRM1 (0.39) OPRM1OPRD1OPRK1OPRL1CYP46A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ARRAY BIOPHARMA INC. (US) 2023-05-16 US disclosed
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF RAPT THERAPEUTICS INC (US) 2021-10-14 US disclosed
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-31 US disclosed
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180148445-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885
US-11648243-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, BRAF, RAF1 OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885
US-20210317134-A1 UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF USP7, SENP7, USP8 OPRM1 4147/4885OPRD1 3897/4885OPRK1 3916/4885
US-20180133207-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885
US-20180134703-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, BRAF, RAF1 OPRM1 3497/4885OPRD1 2909/4885OPRK1 2369/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.